The ATM increase signals ongoing cash needs and likely continued dilution. With $3.4M already sold and a $13M market cap, the company is relying on equity financing to fund operations. Monitor upcoming quarterly filings for cash runway and any pipeline catalysts that could alter the dilution trajectory.
SNGX drugs
SNGX drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 29 $0.9100entry
- T+1 · 6mo ago −9.31%α −9.58% · $0.8253
- T+5 · 6mo ago −47.25%α −46.96% · $0.4800
- T+20 · 5mo ago −56.04%α −54.25% · $0.4000
- T+60 · 3mo ago −55.53%α −56.71% · $0.4047
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Soligenix filed an 8-K to increase the maximum aggregate offering amount under its existing at-the-market (ATM) equity facility with Rodman & Renshaw by $2,956,000, bringing the total to $6,406,000. The company had previously sold approximately $3,445,000 under the facility. This represents ongoing equity dilution for a micro-cap biotech with a $13M market cap.
Key Facts
- ATM facility increased by $2,956,000 to a total maximum of $6,406,000
- Prior sales under the facility totaled approximately $3,445,000
- Shares sold through Rodman & Renshaw under the existing Sales Agreement dated January 23, 2026
- Company market cap is approximately $13M, making the incremental offering ~23% of market cap
Financial Impact
Potential additional dilution of up to $2.96M in gross proceeds, representing ~23% of current $13M market cap
Risk Factors
- Further dilution from continued ATM sales
- Potential inability to raise sufficient capital if stock price declines
- No disclosed revenue or near-term catalyst to offset dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-067649 |
| Document: sngx-20260528xex23d1.htm | 0001104659-26-067649 |
| Document: sngx-20260528xex5d1.htm | 0001104659-26-067649 |
| Document: 0001104659-26-067649-index-headers.html | 0001104659-26-067649 |
| Document: 0001104659-26-067649-index.html | 0001104659-26-067649 |
| Document: 0001104659-26-067649.txt | 0001104659-26-067649 |
Track record
7 reports on SNGX
4 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +69.30% at T+20 after the Apr 3, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $0.3350 Now $0.2900 −13.43% settles Feb 4
- Nov 2, 202614d ago SC 13G/A Neutral 2/10 Entry $0.3612 Now $0.2900 −19.71% settles Jan 29
- Jun 26, 202620w ago 8-K Bearish 6/10 Entry $0.4000 to $0.3850 Now $0.2900 +27.50% ▲ +3.75% +8.14% vs SPY
- Jun 26, 202620w ago 424B5 Bearish 7/10 Entry $0.4000 to $0.3850 Now $0.2900 +27.50% ▲ +3.75% +8.14% vs SPY
- May 28, 202624w ago 8-K Bearish 5/10 Viewing Entry $0.9100 to $0.4047 Now $0.2900 +68.13% ▲ +55.53% +56.71% vs SPY
- May 28, 202624w ago 424B5 Bearish 6/10 Entry $0.9100 to $0.4047 Now $0.2900 +68.13% ▲ +55.53% +56.71% vs SPY
- Apr 3, 202632w ago EFFECT Bearish 6/10 Entry $1.14 to $0.3970 Now $0.2900 +74.56% ▲ +65.18% +78.64% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers